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Human colon cancer harbors a small subfraction of
tumor-initiating cells (TICs) that is assumed to be
a functionally homogeneous stem-cell-like popula-
tion driving tumor maintenance and metastasis
formation. We found unexpected cellular heteroge-
neity within the TIC compartment, which contains
three types of TICs. Extensively self-renewing long-
term TICs (LT-TICs) maintained tumor formation in
serial xenotransplants. Tumor transient amplifying
cells (T-TACs)with limitedor no self-renewal capacity
contributed to tumor formation only in primary mice.
Rare delayed contributing TICs (DC-TICs) were
exclusively active in secondary or tertiary mice.
Bonemarrowwas identifiedas an important reservoir
of LT-TICs. Metastasis formation was almost exclu-
sively driven by self-renewing LT-TICs. Our results
demonstrate that tumor initiation, self-renewal, and
metastasis formation are limited to particular sub-
populations of TICs in primary human colon cancer.
We identify LT-TICs as a quantifiable target for thera-
pies aimed toward eradication of self-renewing
tumorigenic and metastatic colon cancer cells.
INTRODUCTION
All terminally differentiated cells of the colon epithelium are
generated by a small number of multipotent stem cells that
reside at the basis of finger-like invaginations of the colon
epithelium, the crypts (Barker et al., 2008). Because of the short
lifespan of differentiated colon epithelial cells, the intestinal
stem cell system has to produce more than 6 3 1014 colono-
cytes during the lifetime of an individual (Ricci-Vitiani et al.,
2009). To be capable of rapidly adapting to changes in cell
demand in a tightly regulated way, multiple distinct stem and
progenitor cell types are hierarchically organized. Long-lived
stem cell function has been assigned to cells located at theCbottom of the crypts and close-by in the so-called +4 position
(Barker et al., 2007; Sangiorgi and Capecchi, 2008). These cells
give rise to a larger number of more rapidly dividing transient
amplifying progenitor cells moving their progeny up the crypt
walls.
Accumulating evidence indicates that stem cell-like properties
can also be detected in distinct cells within malignant tumors of
the colon epithelium (Dalerba et al., 2007; Huang et al., 2009;
O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Vermeulen et al.,
2008). A subfraction of tumor-initiating cells (TICs) has been
shown to be exclusively capable of tumor formation in immuno-
deficient mice (Dalerba et al., 2007; Huang et al., 2009; O’Brien
et al., 2007; Ricci-Vitiani et al., 2007). The estimated frequency
of TICs varies between different tumors and tumor entities and
strongly depends on the genetic background of the immunode-
ficient mouse strain used for their detection, with the NOD/SCID
IL2R gamma chain-deficient strain (Il2RG/) allowing the most
sensitive detection reported (Merlos-Sua´rez et al., 2011; Quin-
tana et al., 2008, 2010). Nevertheless, in contrast to highly malig-
nant melanoma, colon cancer TICs have been shown to be rare
and associated with a distinct phenotype (Merlos-Sua´rez et al.,
2011; O’Brien et al., 2007; Ricci-Vitiani et al., 2007). TICs share
key biological properties with normal stem cells. They regenerate
tumorigenic as well as nontumorigenic cells in vivo (Dalerba
et al., 2007; Huang et al., 2009; O’Brien et al., 2007; Ricci-Vitiani
et al., 2007), but molecular proof of their ability to self-renew
in vivo at the clonal level is still missing. TICs in solid tumors
are generally assumed to be a functionally homogeneous popu-
lation of cancer stem cells that drives tumor maintenance and
metastasis formation (Visvader and Lindeman, 2008). We
reasoned that only a small subfraction of such cells within
each tumor is truly long-term tumorigenic in transplantation
models. We hypothesized that the metastasis-forming potential
of human colon TICs should be detectable as a measurable
capacity to self-renew, and that, similar to earlier observations
in leukemia, distinct classes of stem-like and progenitor-like
cell subpopulations should be present in solid cancers (Eisterer
et al., 2005; Hope et al., 2004). Using a molecular tracking
strategy, we identified three types of TICs with specific roles in
tumor maintenance and metastasis formation that form a tumor
stem cell hierarchy: extensively self-renewing long-term TICs,ell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc. 357
Table 1. Patient Characteristics and Metastases Formation of Xenografts in Mice
Patient
Number Age/Sex Tumor Site
Stage
(UICC)
Tumor
Differentiation
Mice with
Metastasesa
No. Liver
Metastases
No. Lung
Metastases
No. Spleen
Metastases
P1 71/m liver metastasis IV moderate 3/39 - - 3
P2 54/m liver metastasis IV moderate 26/37 26 - 1
P3 67/m lung metastasis IV moderate-poor 0/17 - - -
P4 53/m right colon IV poor 14/18 14 2 -
P5 53/f liver metastasis IV moderate 0/9 - - -
P6 64/m liver metastasis IV moderate 0/15 - - -
a Total number of mice with metastases; metastases can occur in different organs of individual mice.
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uting (DC-) TICs.RESULTS
Hierarchy in Human Colon Cancer Spheres
To analyzewhether human colon cancer is formedby a heteroge-
neous precursor cell compartment, we cultured cell suspensions
from primary human colon cancer specimens under conditions
that favor the growth of floating cell aggregates, previously
described as tumor spheres (Table 1; Lee et al., 2006; Ricci-
Vitiani et al., 2007; Todaro et al., 2007). Tumor spheres efficiently
maintain tumorigenic TICs without restriction to a particular
surface phenotype. Only a small proportion of all cells within
individual patient tumors initially formed tumor spheres (P1,
0.0005%; P3, 0.00025%; P5, 0.0003%; P6, 0.001%; P2 and
P4, n.a.). Histological examination of all spheres excluded
the presence of nonneoplastic cells within these cultures (see
Figure S1 for detailed phenotypic characterization, available
online). In one patient sample, enough cells were available to
directly compare xenograft tumor formation of freshly isolated
tumor cells with tumor sphere cells. Xenotransplantation of
2.53 104 tumor sphere cells into the kidney capsule of immuno-
deficient IL2RG/ mice reproducibly formed tumors whereas
no tumor growth was observed after transplantation of 2 3 106
fresh tumor cells derived from the respective original tumor
sample (P1), providing strong evidence that TICs were enriched
in the sphere cultures.
To functionally characterize the cellular composition of tumor
spheres, we quantified the proliferation, sphere-forming, and
self-renewal potential of single isolated sphere cells from
three individuals. In two of three patients, more than 90% of
sphere culture-derived single cells did not grow into new
spheres but were limited in proliferation capacity or even postmi-
totic (Figure 1A). Replating of dissociated single tumor sphere
cells revealed that only a minority of cells from each clonal
sphere renewed into new spheres. The percentages of self-re-
newing sphere-forming cells, cells with low proliferative activity,
and postmitotic cells remained remarkably stable over several
rounds of single-cell replating experiments, clearly demon-
strating that all three types were derived from single sphere-
forming cells (Figure 1B). Thus, tumor spheres contain tumor
cell subfractions of considerable heterogeneity that are orga-
nized in a linear hierarchy.358 Cell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc.Molecular Marking of TICs
Wehypothesized that the observed cellular heterogeneity in vitro
might reflect TICs with a different self-renewal potential in vivo.
To visualize the contribution of individual human colon cancer
TIC clones to tumor formation and to track their self-renewal
activity in serial transplantation, we used an innovative molecular
marking approach with lentiviral vectors (Figure 1C). We
enriched colon cancer stem cells in sphere cultures for two to
five passages to avoid marking of bystander nonneoplastic cells
(Figure S1). Tumor spheres were then dissociated and trans-
duced with a GFP-encoding lentiviral vector. We used a SIN
lentiviral vector in which the enhancer elements were deleted
from the 30-LTR to minimize the likelihood of activating neigh-
boring cellular genes and avoid interference with murine retrovi-
ruses (Cartier et al., 2009; Montini et al., 2009). From each
sample we initially transplanted 2.5 3 104 to 1 3 105 marked
tumor sphere cells under the left kidney capsule of IL2RG/
mice. Visible tumors formed in 131 of 140 serial transplanted
mice (P1, 39/39; P2, 37/42; P3, 17/17; P4, 18/18; P5, 8/9; P6,
12/15). Xenografted tumors from two patient samples originat-
ing from liver metastases and one patient sample derived from
a colon tumor metastasized in the mice (Table 1). 4 to 21 weeks
after primary transplantation, tumors andmetastases (Figure 1D)
were explanted and aliquots of dissociated tumor and metas-
tasis cells were saved for vector insertion site analyses. We seri-
ally transplanted tumor and metastasis cells from each sample
into secondary and tertiary recipient mice (Figure 1C). Marking
efficiency varied between different patient samples. The propor-
tion of transduced cells in xenografts ranged from 1% to 97%
(P1, 1%–7%; P2 and P3, 61%–97%; P4, n.d.). Marked TICs
contributed equally to subsequent generations of xenotrans-
planted tumors in serial transplantation, indicating that represen-
tative fractions of TICs had been transduced. We found no
detectable differences in growth rate, histology (Figure S1 and
Table S1), or metastasis formation between lentivirally marked
and unmarked control tumors from the same patients.
A Subpopulation of TICs Self Renews
We amplified clone-specific insertion site fusion sequences
between the vector long terminal repeat (LTR) and its genomic
insertion flank by highly sensitive linear amplification-mediated
PCR (LAM-PCR) and sequenced by next generation high-
throughput sequencing (Boztug et al., 2010; Cartier et al.,
2009; Glimm et al., 2005; Hacein-Bey-Abina et al., 2003; Ott
et al., 2006; Schmidt et al., 2007). To reduce the detection bias
Figure 1. Genetically Marked Human Colon Cancer Tumor-Initiating Cells Form Tumors and Metastases in Immunodeficient Mice
(A) Individual sphere cells from three patients (P1–P3) were cloned into 96-well plates. Spheres contain three distinct cell types defined by their proliferative
activity. The relative proportion of these cell types varied between patient samples.
(B) The relative proportion of each cell type defined by their proliferative capacity remained stable within spheres after serial replating (1, 2, 3 = generation).
Results are shown as mean values ± SE from three independent experiments.
(C) Experimental strategy. Tumor-initiating cells (TICs) from primary human colon cancer specimens were enriched in sphere cultures, genetically marked by
lentiviral transduction, and injected under the kidney capsule (KC) of IL2RG/mice. Primary tumors (T) or metastases (M) were serially transplanted into multiple
secondary recipients. Genomic integration sites were monitored by LAM-PCR and sequenced to analyze the activity of individual TIC clones in vivo.
(D) Abdominal MRT scans of mice transplanted with human TICs under the KC. Mice transplanted with sphere cells derived from P2 developed liver metastases.
Red arrow indicates tumor under KC; yellow arrow indicates liver metastases.
See also Figure S1 and Table S1.
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reanalyzed two to four times using different restriction enzymes
(Gabriel et al., 2009). In each sample, 500 ng DNA per enzyme
was analyzed corresponding to7.53 104 cells. In all individual
primary xenograft tumors (Figure 2A) derived from individual
patients, we detected multiple unique vector integration sites
(IS) in repeated experiments (3-82), indicating that multiple
marked TICs contributed to tumor formation in mice. To enu-
merate the number of IS per transduced individual TICs, we iso-
lated single cells from primary xenograft tumors transduced with
the highest multiplicity of infection (MOI) and expanded them in
sphere cultures. Between one and three IS (mean = 1.75) were
detected in different single xenograft-derived clonal spheres
by LAM PCR followed by high-throughput sequencing, indi-
cating that we could visualize the activity of more than 30 clones
in primary xenograft tumors. Strikingly, the IS patterns in tumors
from secondary and tertiary xenografts from multiple mice that
had been serially transplanted in parallel with tumor cells fromCthe same primary xenograft were very similar or identical. A
much lower number of IS was present as compared to the orig-
inal primary xenografts (Figures 2B and 2C; see also Figures
S2A–S2I), molecular evidence indicating that only a subpopula-
tion of TICs have continuously self-renewed, retaining the ability
to form tumors in primary, secondary, and tertiary xenografts.
The striking identity of clonal contributions between pairs of
secondary and pairs of tertiary tumors indicates that this pattern
was not generated by a dominant dilution effect or sampling
error (Figure 2B; see also Figure S2). High-throughput IS
sequencing confirmed that, even though we sampled significant
amounts of material at every stage, 15%–60% of all TICs
continued to re-establish tumors in serially transplanted mice
(Figures 2C and 2D; see also Figure S2). In contrast, the majority
of labeled cell clones in primary mice did not contribute to tumor
formation in serial transplantation. We used individual flanking
sequences from a total of 15 clones serially transplanted in
four independent experiments to confirm the presence ofell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc. 359
Figure 2. Distinct Classes of Human Colon Cancer Tumor-Initiating Cells Contribute to Tumor Formation in Immunodeficient Mice
(A) Transduced TICs formed tumors after kidney capsule (KC) transplantation (left); scale bar represents 0.5 cm. HE staining of KC tumor formed by lentivirally
marked sphere cells (right); scale bar represents 50 mm.
(B) Multiple clones contributed to tumor formation in serial transplantation. Each band represents an individual integration site (IS) amplified by LAM-PCR. A
higher number of clones contributed to tumor formation in primary mice than in subsequent tumors in serial transplantation. Mice transplanted with cells from the
same donor xenograft share identical integrations. M, 100 bp marker; -C, negative control; IC, internal control band.
(C and D) High-throughput IS sequencing demonstrated that different subfractions of TIC clones contributed to serial tumor formation. Blue fields visualize
relative contribution of individual clones (in percent) as indicated in color legend.
(E) Tracking PCRwith clone-specific primers against individual clones serially transplanted in four independent experiments confirmed clone kinetics identified by
high-throughput sequencing. LT-TIC, long-term TIC; T-TAC, tumor transient amplifying cells; DC-TIC, delayed contributing TIC; asterisks indicate tracking PCR in
one 1st and two 2nd mice. Clones without asterisk were tracked in 1st, 2nd, and 3rd generation mice. M, 100 bp marker; -C, negative control. Each colored box
represents an individual IS amplified by LAM-PCR and sequenced by 454/GS FLX Titanium sequencing technology. 1–3, 1st–3rd xenograft generation; P1–P4,
patient number 1–4; KC, kidney capsule. Black arrows indicate serial transplantation under the kidney capsule. Chr, chromosome; IS, integration site; P(1-6)-X,
exp. number. Color code indicates the relative contribution (in percent) of individual IS within a given sample.
(F) TIC subpopulations are present in fresh tumor material (P6) without culture. Each band on the gel represents an individual integration site amplified by LAM-
PCR. Smear indicates highly polyclonal samples. M, 100 bp marker; -C, negative control; IC, internal control band.
(G) Multiple clones contribute to tumor formation after transplantation of transduced fresh primary tumor cells from patient 6 (P6) into primary recipient mice.
Primary xenografts were serially transplanted into two secondary recipients and one tertiary recipient.
See also Figure S2 and Table S2.
Cell Stem Cell
Distinct Classes of Colon Cancer Stem Cellsparticular IS in LT-TICs and T-TACs, validating the kinetics as
measured by high-throughput IS sequencing (Figure 2E).
To test whether the occurrence and kinetics of the different
types of TICs observed could alternatively be explained by
stochastic activity of similar clones, computer simulations
were done. An R-based simulation computer program was
developed that calculates the clonal contribution during serial
transplantation assuming a stochastic model for the distribution360 Cell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc.of tumorigenic cells (Supplemental Experimental Procedures).
The expected number of clones in two secondary recipients
transplanted with cells from the same donor mouse and in
subsequently transplanted tertiary mice was calculated on
the assumption that all cells are equal (‘‘null hypothesis’’).
The simulated distribution of clones assuming the null hypoth-
esis did not represent the experimental results in terms of
number of clones detected in secondary (p < 0.001) and tertiary
Cell Stem Cell
Distinct Classes of Colon Cancer Stem Cells(p < 0.001) transplanted tumors as well as overlapping clones
detected in both secondary tumors derived from the same
primary mouse (p < 0.001). The results strongly disagree with
a stochastic model, demonstrating that our experimental find-
ings cannot be explained by a stochastic contribution of marked
clones in serially transplanted mice.
Thus, gene marking conclusively demonstrated that two types
of TICs contributed to tumor formation in primary xenografts:
a low number of LT-TICs that were actively self-renewing in vivo
(and formed tumors in secondary and subsequent transplant
generations) and a higher number of T-TACs with no or very
limited self-renewal potential.
Delayed Contributing TICs Reactivate in Serial Tumors
Surprisingly, not all TICs responsible for long-term tumor growth
had contributed quantitatively to the primary tumor source for
serial transplantation. We consistently detected a low number
of clones in secondary or tertiary xenografts that were not
detectable in primary xenografts by both high-throughput
sequencing (Figures 2B–2D; see also Figures S2A–S2I) and
specific PCR amplification (Figure 2E). The low or absent activity
of these clones in primary xenografts indicates that some TICs
had been in a state in the primary tumor in which they did not
quantitatively contribute to tumor formation but were recruited
to tumor formation after serial transplantation (delayed contrib-
uting [DC-] TICs).
IS analysis visualized the same clonal behavior of LT-TIC and
T-TAC activities among colon cancer stem cells in primary and
serial transplantation of lentiviral-marked fresh human colon
cancer samples, showing that clonal TIC heterogeneity had not
been introduced by sphere culture conditions (Figures 2F and
2G; see also Figure S2J).
LT-TICs Drive Metastasis In Vivo
Migrating cancer stem cells have been implicated in metastasis
formation (Hermann et al., 2007; Wellner et al., 2009). We
reasoned that it is unlikely that all TICs from an individual colon
cancer can formmetastasis because metastasis-forming poten-
tial should require self-renewal potential of TICs. To investigate
which of the different types of TICs identified by molecular
marking are the principal source of metastases, we analyzed
series of xenografts derived from patient samples that had
metastasized into the liver (P2, P4), the spleen (P1, P2), and
the lung (P4) of the mice (Table 1). No metastasis formation
was detectable in xenografted mice transplanted with sphere
cells from P3 or primary cells from P5 and P6, irrespective of
the tumor size. The original patient tumor site did not predict
metastasis formation in murine xenografts. Spheres able to
metastasize into the mouse liver were derived from liver metas-
tasis (P2) and a primary colon tumor (P4), whereas sphere
cultures incapable of metastasis formation into the mouse liver
originated from lung (P3) or liver (P1, P5, P6) metastases. Inser-
tional marking allowed us to directly assess metastasis-forming
potential of individual TICs and self-renewal of metastasizing
TICs. We dissociated whole livers containing metastases (Fig-
ure 3A) from 23 mice, spleens from 4 mice, and lungs from 2
mice, and we analyzed lentiviral IS in large aliquots of each. In
most instances, multiple clones contributed to metastasis
formation (Figures 3B and 3C; see also Figures S3A–S3F). MoreCthan 90% of all LT-TIC clones present in the primary transplant
location of metastasized xenografts had initiated metastases.
In contrast, only a 22% subfraction of all clones detected as
T-TACs in primary tumor formation formed metastases. It is
conceivable that asymmetric divisions of LT-TICs may have
resulted in asymmetric distribution of self-renewal potential
between daughter cells in local tumors and those in metastases.
To further determine the self-renewal potential of metastatic
TICs, we serially transplanted cells from metastasized livers
in two experiments (Figure 1C; see also Figures S3G and
S3H). Two of three and eight of eight metastatic clones, respec-
tively, formed serial tumors andmetastases in subsequent trans-
plantation recipients, further confirming that the vast majority of
metastases are driven by LT-TICs that possess self-renewal
potential.
TICs Home to and Persist in the Bone Marrow
Disseminated tumor cells in multiple organs and circulating
tumor cells in the peripheral blood are frequently detectable in
patients both in local as well as metastasized stages of colon
cancer (Lindemann et al., 1992; Schlimok et al., 1990). Even if
the detection of disseminated tumor cells in the bone marrow
(BM) correlates with poor prognosis in colon cancer patients, it
is unclear whether the presence of tumor cells in the BM simply
reflects aggressive tumor growth or whether these disseminated
tumor cells have tumor stem cell potential and can therefore be
the source of systemic relapse (Lindemann et al., 1992). To
understand which TIC clones disseminate and whether these
disseminated cells have tumor-initiating potential, we collected
peripheral blood and BM cells from 17 mice with metastasized
marked xenograft tumors. Even though multiple clones contrib-
uted to primary tumors and metastases in the same mice, only
single clones were present in the peripheral blood of individual
mice, indicating that metastasis-forming tumor cells only tran-
siently enter the circulation. In contrast, multiple disseminated
TIC clones homed to the BM and formed metastases in the liver
(Figures 3D and 3E; see also Figures S4A and S4B). We evalu-
ated cancer stem cell activity of tumor cells in the murine BM
by sphere formation in vitro and by transplanting 7.5 3 106 to
2.1 3 107 unseparated BM cells into the kidney capsule of
secondary recipient mice.We detected 2–17GFP+ sphere-form-
ing cells in 1 3 106 murine BM cells (Figure 3F). Marked tumors
formed in four of four mice that were transplanted with BM into
the kidney capsule, clearly demonstrating that disseminated
tumor cells not only reside in the BM but retain tumor-initiating
potential (Figure 3G; see also Figure S4C). These data provide
direct evidence that the BM can serve as a reservoir for meta-
static TICs.
DISCUSSION
Our results reveal an unexpected heterogeneity of tumor-initi-
ating cells in human colon cancer. LT-TICs, T-TACs, and DC-
TICs form a malignant stem cell compartment with a hierarchical
organization resembling normal stem cell systems (Alonso and
Fuchs, 2003; Glimm et al., 2001; Stingl et al., 2006). T-TACs
are predominant in tumor formation but lack detectable self-
renewal and metastasis-forming potential, suggesting that they
might not be the relevant target to prevent long-term tumorell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc. 361
Figure 3. LT-TICs Drive Metastasis Formation and Disseminate into the Bone Marrow
(A) Transduced TICs metastasized into the liver of mice after transplantation under the kidney capsule (KC) (top); scale bar represents 1 cm. HE staining of
metastatic liver slice (bottom); scale bar represents 50 mm.
(B) Identical bands were present in KC tumors and corresponding LM in serial transplantation, indicating that multiple LT-TIC clones that contributed to serial
tumor formation under the KC formed liver metastasis (LM).
(C) High-throughput 454 sequencing confirmed that multiple LT-TIC clones contributed to metastasis formation in liver and spleen.
(D and E) Disseminated tumor cell clones were detected in the bone marrow (BM) and the peripheral blood (PB) of mice with metastasizing tumors under the KC.
(F) BM cells from mice with metastasizing tumors formed GFP-expressing tumor spheres in vitro and tumors after transplantation in vivo. Magnification 20-fold.
TL, transmission light; GFP, green fluorescent protein in fluorescence light.
(G) Transplantation of BM cells derived from mice transplanted with metastasizing sphere cultures of P2 under the kidney capsule led to long-term tumor
formation driven by LT-TICs residing in the BM.
M, 100 bp marker; -C, negative control; IC, internal control band. Each band represents an individual IS amplified by LAM-PCR and sequenced by 454/GS FLX
Titanium sequencing technology. 1–4, 1st–4th xenograft generation; P2, patient number 2; KC, kidney capsule; LM/SM, liver/spleen metastasis; PB, peripheral
blood; BM, bone marrow. Black arrows indicate serial transplantation under the kidney capsule, gray or brown arrows indicate liver or spleen metastases, red
arrows indicate corresponding PB or BM. Chr, chromosome; IS, integration site; P2-X, exp. number. Color code indicates the relative contribution (in percent) of
individual IS within a given sample.
See also Figures S3 and S4.
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renew and readily metastasize. Strikingly, the clonal activity after
secondary and tertiary transplantation and in serially trans-
planted metastases is remarkably stable and reproducible, ex-
cluding a stochastic appearance and disappearance of clones.362 Cell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc.A particular strength of genetic marking is that the activity
of the different types of TICs could be monitored without
isolating TICs in a limiting dilution situation, as the full in vivo
development of T-TACs, LT-TICs, and DC-TICs may be sup-
ported by cellular interactions. The number of marked TICs
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patient samples. Because the seeding efficiency is constant in
serial transplantation and genetic marking allows us to follow
up individual TICs, variability of the initial TIC frequency in
samples derived from different patients does not affect the
statistical validation of the data.
Coexistence of subclones harboring different genetic lesions
within individual leukemia samples and solid tumors has been
demonstrated (Campbell et al., 2010; Notta et al., 2011; Yachida
et al., 2010). Even though we cannot rule out some genetic diver-
sity in the colon samples analyzed in this study, several lines of
evidence indicate that genetic heterogeneity did not contribute
significantly to the functional differences between the three
types of TICs. Single isolated tumor cells formed spheres that
again contained three cell types defined by differences in their
proliferative and self-renewal activity. The proportion of these
cell types in spheres from individual patient samples remained
stable through subsequent generations of replating experi-
ments, strongly arguing against underlying additional mutations.
All these cells were derived from single sphere-forming cells,
underscoring the linearity of the hierarchy. Some sphere cultures
were derived from clonal metastases in patients and thereby
derived by definition from an individual metastasiogenic self-
renewing tumor cell that must have been the precursor of LT-
TICs, T-TACs, and nontumorigenic cells in the mice. Moreover,
in serial transplantations, we did not observe any histological
dedifferentiation or acceleration in the growth of the tumors
over subsequent generations, further arguing against a rapid
and simultaneous acquisition of additional genetic events in
multiple TIC clones.
The murine kidney capsule is very permissive for the growth of
xenotransplanted tumors and IL2RG/ mice may support the
growth of all or most melanoma cells transplanted (Quintana
et al., 2008). In contrast, our clonal marking results clearly dem-
onstrated that this was not the case in the colon cancer xeno-
grafts, because profound functional differences of the different
types of TICs were uncovered. Moreover, up to 1 3 105 marked
sphere-forming cells were transplanted into individual recipient
micebut only less than 100clones contributed to xenograft tumor
formation, indicating that sphere formation and tumor initiation
were not driven by exactly overlapping cell populations. Even
though serial replating demonstrated that sphere-forming cells
gave rise to large numbers of daughter cells again able to form
spheres in vitro and thereby by definition self-renewed, only
a subfraction had the capacity to initiate a tumor after transplan-
tation (Ricci-Vitiani et al., 2007). Thus, tumor formation in mice is
amuchmore stringent requirement and the only reliable assay to
detect tumor-initiating cells by testing additional biological prop-
erties compared to in vitro sphere formation.
Tumor formation, self-renewal, and metastasis formation are
found disjunct in subpopulations, indicating that they must be
regulated independently. Our model of molecular labeling and
highly enriching the distinct subpopulations of TICs enables
further studies aimed at elucidating the underlying molecular
mechanisms governing the transition between the self-renewing
and transient amplifying phenotypes. It will allow testing of novel
therapeutics targeting key regulators of this process toward
blocking of self-renewal and metastasis formation in human
colon cancer.CEXPERIMENTAL PROCEDURES
Purification and Culture of Colon Cancer Cells
Primary human colon cancer samples were obtained from Heidelberg Univer-
sity Hospital in accordance with the declaration of Helsinki. Informed consent
on tissue collection was received from each patient, as approved by the
University Ethics Review Board. Single-cell suspensions were prepared from
primary tumor samples and cultured as spheres in the presence of FGF and
EGF (Supplemental Experimental Procedures).
Single-Cell Cloning of Tumor Sphere Cells
Sphere cultures or single spheres were dissociated to a single-cell solution
and 1 cell per well was seeded in a 96-well plate. Seeding efficiency as deter-
mined by microscopy was 30%. Wells containing single cells were used for
subsequent analysis. Cells were observed over 14–21 days, depending on
the growth rate of distinct patient-derived cultures. Cells defined as postmi-
totic did not divide and survived up to 5 days; sphere-forming cells divided
several times and formed small cell aggregates, which subsequently devel-
oped into single tumor spheres.
Xenotransplantation of Tumor Cells
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (Il2rg/) mice were obtained from the Jack-
son Laboratory (Bar Harbor, ME) and housed at a specific-pathogen-free
animal facility according to all applicable laws and regulations subsequent
to approval by the institution’s animal care and ethical committee. Colon
cancer sphere cells or fresh human colon cancer cells were transplanted under
the kidney capsule of Il2rg/ mice (Supplemental Experimental Procedures).
Reverse-Transcription PCR
RNA from tumor sphere cultures was extracted with RNA Mini Kit (QIAGEN).
500 ng of total RNA were transcribed with Superscript 3 First Strand Synthesis
Kit (QIAGEN). PCR was performed on cDNA with gene-specific primer pairs
(Table S2).
Lentiviral Vector Production and Transduction
VSV-G pseudotyped third-generation self-inactivating lentiviral vector encod-
ing for EGFP under the control of the human CMV promoter was used. Vector
particle-containing supernatant was generated as described (Dull et al., 1998)
with Polyethylenimine (Sigma) for transfection. Vector stocks were concen-
trated by ultracentrifugation.
For lentiviral transduction, dissociated colon cancer cells were transduced
with Viromag R/L beads (OZbiosciences) at multiplicities of infection from 1
to 1000.
LAM-PCR Insertion Site and Sequence Analysis
30LTR-mediated LAM-PCR analyses were accomplished as described
(Schmidt et al., 2007). Raw LAM-PCR amplicon sequences were separated
according to the introduced barcode, trimmed, and further aligned to human
genome assembly (HG19, GRCh37) (Supplemental Experimental Procedures).
Integration Site-Specific Tracking PCR
IS-specific vector-genome junctions were amplified by PCR on 15–200 ng of
DNA isolated from xenografted kidney capsule tumors. Nested or seminested
PCRs were performed to amplify rare sequences from polyclonal samples or
sequences from low DNA amounts (<30 ng) (see also Table S2).
Statistical Analyses
For statistical modeling, an R-based simulation computer program was devel-
oped (Supplemental Experimental Procedures).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
doi:10.1016/j.stem.2011.08.010.ell Stem Cell 9, 357–365, October 7, 2011 ª2011 Elsevier Inc. 363
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